United StatesAging Population▲
CVRx Secures Devoted Health Coverage for Barostim Therapy
CVRx announced that Devoted Health has issued a Medicare Advantage coverage policy for its Barostim therapy, effective July 17, 2026, covering patients under the current FDA-approved indication and those in the BENEFIT-HF clinical trial. This expands reimbursement access across Devoted Health's roughly 466,000 Medicare Advantage members in 29 states. Combined with Humana's earlier coverage, CVRx now has Medicare Advantage coverage representing about 21% of total enrollment, strengthening its commercial outlook. Shares have traded flat following the news, with the stock down 57.2% year to date versus the industry's 6.7% decline. The company also reported second-quarter 2026 revenues of $15.7 million, up 16% year over year, and expanded its U.S. active implanting centers to 258.
About megatrends
Aging Population › Medical Devices for the Aging Body ▲Demand
CVRX · Regulation · Positive Devoted Health issued a Medicare Advantage coverage policy for CVRx's Barostim therapy, expanding reimbursement access to ~466,000 members across 29 states.
CVRX · Demand · Positive Q2 2026 revenues rose 16% YoY to $15.7M and U.S. active implanting centers expanded to 258, indicating growing adoption.
